Resumo

VILLAESCUSA BLANCO, Rinaldo et al. Detection of antibodies to PM:. Rev Cubana Hematol Inmunol Hemoter [online]. 2010, vol.26, n.1, pp. 27-32. ISSN 1561-2996.

Promyelocytic leukemia (PML) is associated with unique genetic features including the t reciprocal translocation (15; 17) (q22; q22) with PML-RARa, which accounted for more than 95 % of fusion protein in PML and is a potential target of immune response. The current treatments known as differentiation therapies combine the trans-retinoic acid (TRA) and the anthracyclines, as well as the trioxide arsenic (As₂0₃); become in a long-term survival and the potential cure in about the 70 to 80 % of patients. In studies conducted in LPM-mice immunized with a DNA vaccine made the PML-RARa oncogene fusion to C fragment of tetanus toxin as coadjuvant together with TRA were antibodies high titers. It was possible to achieve a significant survival among 120-130 days compared with that of placebo-mice. In our paper it was detected the presence of antibodies to PML-RARa fusion protein in different phases of treatment indicating the response to these patients to tumor antibody. The anti-PML-RARa were detected in those non-treated patients and in induction fusion, but not in consolidation and maintenance, thus its potential usefulness as cellular differentiation marker from presence or absence of fusion protein un leukemic cell.

Palavras-chave : Promyelocytic leukemia; PML-RARa fusion protein; anti-PML-RARa antibodies.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )